CRBU FY 2024 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-71.0% YoY

Gross Profit

$6M60.7% margin

Operating Income

-$167M-1667.2% margin

Net Income

-$149M-1491.9% margin

EPS (Diluted)

$-1.65

Cash Flow

Operating Cash Flow

-$138M

Free Cash Flow

-$145M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$313M

Total Liabilities

$60M

Stockholders' Equity

$253M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$34M	-71.0%
Gross Profit	$6M	$31M	-80.4%
Operating Income	-$167M	-$116M	-43.6%
Net Income	-$149M	-$102M	-46.1%